龚艳君,霍勇

• 1: 北京大学第一医院心内科
• 2:北京大学第一医院心内科

摘要(Abstract)：

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 龚艳君,霍勇

参考文献(References)：

• [1]PanumPL.Experimentelle Beitrage zur Lehre von der Embolie.Vir-chows Arch Anat Physiol,1862,25:308-338.
• [2]Flory CM.Arterial occlusions produced by emboli fromeroded aortic atheromatous plaques.AmJ Clin Pathol,1945,21:549-553.
• [3]Kannel WB.Contributions of the FraminghamStudy to the conquest of coronary artery disease.AmJ Cardiol,1988,62:1109-1112.
• [4]Falanga V,Fine MJ,Kapoor WN.The cutaneous manifestations of cholesterol crystal embolization.Arch Dermatol,1986,122:1194-1199.
• [5]Gore I,McCombs HL,Lindquist RL.Observations on the fate of cholesterol emboli.J Atheroscler Res,1964,4:527-535.
• [6]Fine MJ,Kappor W,Falanga V.Cholesterol crystal embolization:a reviewof221cases in the English literature.Angiology,1987,38:769-784.
• [7]Moolenaar W,Lamers CBHW.Cholesterol crystal embolizationinthe Netherlands:areviewof842casesfiledinthe Dutch National Pathol-ogy Information Systemfrom1973through1994.Arch Intern Medi-cal,1996,156:653-657.
• [8]Maurizi CP,Barker AE,Trueheart RE.Atheromatous emboli.Arch Pathol,1968,86:528-534.
• [9]Belenfant X,Meyrier M,Jacquot C.Supportive treatment improves survival in multivisceral cholesterol crystal embolism.AmJ Kidney Dis,1999,33:840-850.
• [10]Scolari F,Tardanico R,Zani R,et al.Cholesterol crystal embolism:a recognizable cause of renal disease.AmJ Kidney Dis,2000,36:1089-1099.
• [11]Rodot S,Lacour JP,Van Elslande L,et al.Cholesterol crystal em-bolization presenting as erthema induratumof Bazin.Acta Derm Ve-nereol,1995,75:160-161.
• [12]Thahani R,Camargo C,Xavier R,et al.Atheroembolic renal failure after invasive procedures.Natural history based on52biopsy-proven cases.Medicine,1995,74:350-358.
• [13]Frock J,Bierman M,Hammeke M,et al.Atheroembolic renal dis-ease:experience with22patients.Nebr Med J,1994,79:317-312.
• [14]Tanaka M,Matsuo K,Shoda H,et al.Severe hyperreninemic hyper-tension associated withspontaneous renal cholesterol crystal emboliza-tion.Clin Exp Nephrol,2004,8:150-154.
• [15]Moolenarr W,Lamers CBHW.Cholesterol crystal embolizationtothe alimentarytract.Gut,1996,38:196-200.
• [16]Hollenhorst RW.Significance of bright plaques in the retinal arte-rioles.JAMA,1961,178:123-129.
• [17]Mayo RR,Schwartz RD.Redefining the incidence of clinically de-tectable atheroembolism.AmJ Med,1996,100:524-529.
• [18]Graziani G,Santostasi S,Angelini C,et al.Corticosteroidsin Choles-terol Emboli Syndrome.Nephron,2001,87:371-373.
• [19]Wolverton SE.Comprehensive Dermatologic Drug Therapy,1st edn.Philadelphia:W.B.Saunders Company,2001:379-380.
• [20]Woolfson RG,Lachmann H.Improvement inrenal cholesterol emboli syndrome after simvastatin.Lancet1998,351:1331-1332.
• [21]Pitt B,Waters D,Brown WV,et al.Aggressive lipidloweringthera-py compared withangioplastyinstable coronary artery disease.NEn-gl J Med,1999,341:70-76.
• [22]Scwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes.The MIRACLstudy:a randomized controlled trial.JAMA,2001,285:1711-1717.
• [23]Elinav E,Chajek-Shaul T,Stern M.Improvement in cholesterol em-boli syndrome after iloprost therapy.BMJ,2002,324:268-269.
• [24]Grenader T,Lifschitz M,Shavit L.Iloprost in Embolic Renal Fail-ure.MSinai J Med,2005,2:339-341.
• [25]Tamura K,Umemura M,Yano H,et al.Acute renal failure due to cholesterol crystal embolismtreated with LDL apheresis followed by corticosteroid and candesartan.Clin Exp Nephrol,2003,7:67-71.
• [26]Tsunoda S,Daimon S,Miyazaki R,et al.LDLapheresis asintensive lipid-loweringtherapyfor cholesterol embolism.Nephrol Dial Trans-plant,1999,14:1041-1042.
• [27]Navar LG,Harrison-Bernard LM,Nishiyama A,et al.Regulation of intrarenal angiotensin II in hypertension.Hypertension,2002,39:316-322.
• [28]Ruiz-Ortega M,Lorenzo O,Ruperez M,et al.Renin-angiotensin systemandrenal damage:emerging data on angiotensinII as a proin-flammatory mediator.Contrib Nephrol,2001,135:123-127.